mavrik 2f olie i vand emulsion
adama northern europe b.v. - tau-fluvalinat - olie i vand emulsion - 240 g/l tau-fluvalinat
bumper 25 ec emulsionskoncentrat
adama northern europe b.v. - propiconazol - emulsionskoncentrat - 250 g/l propiconazol
orius 200 ew olie i vand emulsion
adama northern europe b.v. - tebuconazol - olie i vand emulsion - 200 g/l tebuconazol
trimaxx emulsionskoncentrat
adama northern europe b.v. - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 175 g/l trinexapac-ethyl ; (~ 156 g/l trinexapac
glypper vandopløseligt koncentrat
adama northern europe b.v. - glyphosat - vandopløseligt koncentrat - 360 g/l glyphosat
starship suspensionskoncentrat
adama northern europe b.v. - mesotrion - suspensionskoncentrat - 100 g/l mesotrion
mavrik vita olie i vand emulsion
adama northern europe b.v. - tau-fluvalinat - olie i vand emulsion - 240 g/l tau-fluvalinat
banjo forte suspensionskoncentrat
adama northern europe b.v. - dimethomorf, fluazinam - suspensionskoncentrat - 200 g/l dimethomorph ; 200 g/l fluazinam
maredo 125 sc suspensionskoncentrat
adama northern europe b.v. - epoxiconazol - suspensionskoncentrat - 125 g/l epoxiconazol
rixathon
sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - antineoplastiske midler - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). kronisk lymfatisk leukæmi (cll)rixathon i kombination med kemoterapi er indiceret til behandling af patienter med tidligere ubehandlet og recidiverende/refraktær kronisk lymfatisk leukæmi. foreligger kun begrænsede oplysninger om effekt og sikkerhed for patienter, der tidligere er behandlet med monoklonale antistoffer, herunder rituximab eller patienter ildfaste materialer til tidligere rituximab plus kemoterapi. se afsnit 5. 1 for yderligere information. reumatoid arthritisrixathon i kombination med methotrexat er indiceret til behandling af voksne patienter med svær aktiv leddegigt, der har haft et utilstrækkeligt respons eller intolerance over for andre sygdomsmodificerende anti-reumatiske lægemidler (dmard), herunder en eller flere tumor nekrose faktor (tnf) - hæmmer behandlinger. rituximab har vist sig at reducere hastigheden af progressionen af ledskader, som målt ved hjælp af x-ray, og til at forbedre den fysiske funktion, når det gives i kombination med methotrexat. granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).